new funding

Houston research organization receives renewal from NASA and millions in funding for space health projects

NASA has renewed its support for Baylor College of Medicine's Translational Research Institute for Space Health. Photo courtesy of NASA

Baylor College of Medicine's Translational Research Institute for Space Health, or TRISH, was granted renewal from NASA this week, which will allow the organization to continue to conduct biomedical research geared at protecting astronauts in deep space through 2028.

According to a statement, NASA reviewed TRISH in December 2020 ahead of the five year mark of its cooperative agreement with BCM's Center for Space Medicine. NASA opted to continue the partnership and now TRISH will receive additional funding of up to $134.6 million from 2022 to 2028.

"NASA has received outstanding value from our bold approach to sourcing and advancing space health research and technologies," institute director Dorit Donoviel, said in a statement. "We are proud to be NASA's partner in its human space exploration mission and to be supporting the research necessary to create new frontiers in healthcare that will benefit all humans."

The institute will focus its efforts on Mars exploration missions in the next six years and has been given three main objectives, according to the release:

  • To build strategic partnerships that will increase the volume of available biometric data on the impact of space travel on health and astronaut performance
  • To build a digital platform that simulates the spaceflight environment and will allow researchers to model and test new health technologies on Earth
  • To develop tissue chip technology that will allow astronauts to place a variety of human cells in lunar orbit during the NASA Artemis research missions to track the effects of space radiation and microgravity on humans

Since TRISH was founded in 2016 it has led the charge in space health research and has partnered with and provided grants to an array of innovative startups to do so.

In 2020 is granted Houston-based Z3VR $50,000 to explore the ways virtual reality can boost physical and mental health among astronauts and it has funded several projects surrounding space radiation levels.

At the time of 2020 review, TRISH had developed and transitioned 34 completed astronaut health and protection projects to NASA and had connected 415 first-time NASA researchers with opportunities to develop space health solutions.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted